New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:05 EDTRXIIRXi Pharmaceuticals granted patent for fibrosis treatment technology
RXi Pharmaceuticals has been granted a patent by the USPTO on its unique self-delivering RNAi compounds, for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI‑109, for the treatment of fibrotic disorders. The patent will expire in 2029.
News For RXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
06:18 EDTRXIIRXi Pharmaceuticals 26M share Spot Secondary priced at 40c
H.C. Wainwright acted as sole book running manager for the offering.
May 27, 2015
16:13 EDTRXIIRXi Pharmaceuticals files to sell common stock and warrants
The Company intends to use the net proceeds from this offering for general corporate purposes, which include, but are not limited to, funding its ongoing and future clinical trials and for general and administrative expenses. The Company may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies or to fund the development of any such complementary businesses, products or technologies that it may acquire in a stock-based acquisition. H.C. Wainwright & Co., LLC will act as exclusive placement agent on a best efforts basis for the offering.
May 21, 2015
09:29 EDTRXIIRXi Pharmaceuticals files to sell 22.5M units
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use